|
Leo I. Gordon, MD is currently Professor of Medicine and Director, Lymphoma Program, Division of Hematology/Oncology at Northwestern University Feinberg School of Medicine. He obtained his medical degree from the University of Cincinnati. He completed his internship and residency in internal medicine at the University of Chicago Hospitals and Clinics. He then went on to complete his fellowship in hematology at the University of Minnesota, and Hematology/Oncology at the University of Chicago.
Dr. Gordon's clinical research interests focus on hematologic malignancies, especially Hodgkin's and non-Hodgkin's lymphomas (NHL) and bone marrow transplantation (BMT). He is co-chair of the Eastern Cooperative Oncology Group (ECOG) Lymphoma Committee. He has conducted clinical trials in NHL incorporating prognostic factor analysis in data assessment. He is leading trials of radiolabeled monoclonal antibodies in low-grade lymphomas and combined modality approaches to mantle cell lymphomas and Hodgkin's disease. In the laboratory, Dr. Gordon is investigating the mechanisms of apoptosis induced by free radicals in lymphoma and myeloma cell lines, developing the concept of redox-regulation as a means of cellular cytotoxicity in cancer.
Dr. Gordon is chair of the Oncological Sciences Study Section at the National Cancer Institute. He also belongs to numerous societies such as the American Federation of Clinical Research, the American Society of Clinical Oncology, the American Society of Hematology and the American Association of Cancer Research. Dr. Gordon has authored over 100 manuscripts for numerous professional publications such as Blood, the New England Journal of Medicine, Cancer Research, Clinical Cancer Research, the Journal of Clinical Investigation and the Journal of Clinical Oncology.
|
